Evidence map›Paper›PMID 31209196›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Renaissance of Modified Charlson Comorbidity Index in Prediction of Short- and Long-Term Survival After Liver Transplantation?

Grzegorz Niewiński, Agata Graczyńska, Szymon Morawiec, Joanna Raszeja-Wyszomirska, Maciej Wójcicki, Krzysztof Zieniewicz, Renata Główczyńska, Michał Grąt

Abstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. [Abdominal organ transplantation in multimorbid patients].Chirurgie (Heidelberg, Germany) · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Grzegorz NiewińskiSecond Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.
Agata GraczyńskaSecond Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.
Szymon MorawiecSecond Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.
Joanna Raszeja-WyszomirskaLiver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.
Maciej WójcickiLiver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.
Krzysztof ZieniewiczDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Renata GłówczyńskaFirst Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Michał GrątDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Orthotopic liver transplantation (OLT) is the standard of care for end-stage liver disease. The Charlson Comorbidity Index (CCI) was originally created to assess the survival rate of patients with chronic diseases, although it was modified and adopted in OLT recipients as CCI-OLT. MATERIAL AND METHODS In total of 248 consecutive liver transplant recipients with viral cirrhosis in 98 (39.5%) patients were included. CCI-OLT was calculated assigning a weight of 3 to chronic obstructive pulmonary disease; weight of 2 to coronary artery disease, connective tissue disease, and renal insufficiency; and a weight of 1 to diabetes mellitus. RESULTS CCI-OLT was significantly correlated with recipient age (p<0.001; R=0.333) and was a significant risk factor for early post-transplant mortality (p=0.004). The presence of diabetes mellitus significantly increased the odds of early mortality (p=0.010). The optimal cut-off for CCI-OLT in prediction of mortality during the first 90 days after transplantation was ≥1, with an AUROC of 0.780 (95% CI: 0.670-0.891; p<0.001). Increasing CCI-OLT was a significant risk factor for worse 5-year post-transplant survival (p=0.001), along with coronary artery disease (p=0.008) and diabetes mellitus (p=0.021). The optimal cut-off for prediction of 5-year mortality for CCI-OLT was ≥1, with the AUROC of 0.638 (95% CI: 0.544-0.733; p=0.004). CONCLUSIONS CCI-OLT is a useful tool for measuring the effect of pretransplant comorbidities and to stratify the effect of risk on both short- and long-term outcomes after OLT. Recipient age and diabetes strongly affected short-term survival after OLT, and metabolic and vascular complications were the leading causes of death at 5 years after OLT.

Indexed as

AdultAgedChronic DiseaseComorbidityConnective Tissue DiseasesCoronary DiseaseDiabetes MellitusEnd Stage Liver DiseaseFemaleGraft SurvivalHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedPoland

Identifiers

PMID31209196
PMCPMC6598463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.